Intramuscular gene transfer of fibroblast growth factor-1 using improved pCOR plasmid design stimulates collateral formation in a rabbit ischemic hindlimb model.
Fibroblast growth factor 1 (FGF1) is an angiogenic factor known to play a role in the growth of arteries. The purpose of this study was to evaluate the usefulness of direct intramuscular injection of an optimized expression plasmid encoding FGF1 to augment collateral formation and tissue perfusion in a rabbit ischemic hindlimb model. Truncated FGF1 fused to the human fibroblast interferon (FIN) signal peptide was expressed from a newly designed plasmid backbone with an improved safety profile for gene therapy applications. In vitro, optimization of plasmid design yielded in a dramatic increase in expression efficiency for FGF1, independent of the presence of a signal peptide, as analyzed by Western Blotting. In vivo, successful transgene expression could be demonstrated by FGF1 immunostaining after gene application. FGF1 plasmid containing FIN signal peptide (100, 500, and 1,000 mug), when injected into ischemic muscle areas of rabbits 10 days after ligation of the external iliac artery, exhibited a pronounced therapeutic effect on collateral formation to the ischemic hindlimb in a dose-depending manner, as assessed by physiological (blood pressure ratio, maximal intra-arterial Doppler flow) and anatomical (angiographic score, histologic evaluation of capillary density) measurements 30 days after therapy, compared to saline or lacZ control plasmid. FGF1 plasmid without a signal peptide sequence resulted in a comparable therapeutic effect on collateral formation at comparable doses (500 and 1,000 mug). Our results indicate that intramuscular FGF1 gene application could be useful to stimulate collateral formation in a situation of chronic peripheral ischemia. The presence of a signal peptide does not seem to be obligatory to achieve bioactivity of intramuscular transfected FGF1. An optimized vector design improved both biosafety of gene transfer and expression efficiency of the transgene, rendering this vector highly suitable for human gene therapy. Therefore, this new generation vector encoding FGF1 might be useful as an alternative treatment for patients with chronic ischemic disorders not amenable to conventional therapy.
Witzenbichler
Bernhard
B
Department of Cardiology and Pneumology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Germany. b.witzenbichler@gmx.de
Mahfoudi
Abderrahim
A
Soubrier
Fabienne
F
Le Roux
Aude
A
Branellec
Didier
D
Schultheiss
Heinz-Peter
HP
Isner
Jeffrey M
JM
D000595:Amino Acid Sequence; D000818:Animals; D001794:Blood Pressure; D002478:Cells, Cultured; D016220:Fibroblast Growth Factor 1 / Q000096:biosynthesis / Q000235:genetics*; D018014:Gene Transfer Techniques; D005822:Genetic Vectors; D006614:Hindlimb / Q000098:blood supply*; D006801:Humans; D007273:Injections, Intramuscular; D016899:Interferon-beta / Q000235:genetics / Q000502:physiology; D007511:Ischemia / Q000628:therapy*; D008297:Male; D008969:Molecular Sequence Data; D018482:Muscle, Skeletal / Q000098:blood supply* / Q000378:metabolism; D018919:Neovascularization, Physiologic; D010957:Plasmids; D021382:Protein Sorting Signals / Q000235:genetics / Q000502:physiology; D011817:Rabbits
D021382:Protein Sorting Signals; D016220:Fibroblast Growth Factor 1; D016899:Interferon-beta